Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Postpartum HIV care continuum outcomes in the southeastern USA.

Chen JS, Pence BW, Rahangdale L, Patterson KB, Farel CE, Durr AL, Antono AC, Zakharova O, Eron JJ, Napravnik S.

AIDS. 2019 Mar 15;33(4):637-644. doi: 10.1097/QAD.0000000000002094.

PMID:
30531320
2.

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.

Dumond JB, Chen J, Cottrell M, Trezza CR, Prince H, Sykes C, Torrice C, White N, Malone S, Wang R, Patterson KB, Sharpless NE, Forrest A.

CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):128-135. doi: 10.1002/psp4.12151. Epub 2016 Dec 29.

3.

p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.

Dumond JB, Collins JW, Cottrell ML, Trezza CR, Prince H, Sykes C, Torrice C, White N, Malone S, Wang R, Patterson KB, Sharpless NE, Forrest A.

CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):120-127. doi: 10.1002/psp4.12150. Epub 2016 Dec 26.

4.

MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.

Cranston RD, Lama JR, Richardson BA, Carballo-DiƩguez A, Kunjara Na Ayudhya RP, Liu K, Patterson KB, Leu CS, Galaska B, Jacobson CE, Parikh UM, Marzinke MA, Hendrix CW, Johnson S, Piper JM, Grossman C, Ho KS, Lucas J, Pickett J, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu AY, Mayer KH, Zorrilla C, Schwartz JL, Rooney J, McGowan I; MTN-017 Protocol Team.

Clin Infect Dis. 2017 Mar 1;64(5):614-620. doi: 10.1093/cid/ciw832.

5.

Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.

Chen J, Malone S, Prince HM, Patterson KB, Dumond JB.

CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):147-57. doi: 10.1002/psp4.12065. Epub 2016 Mar 22.

6.

Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.

Cottrell ML, Prince HM, Allmon A, Mollan KR, Hudgens MG, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Patterson KB, Kashuba AD.

J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):498-506. doi: 10.1097/QAI.0000000000000996.

7.

A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Hudgens MG, Wulff J, Patterson KB, Nelson JA, Kashuba AD.

J Infect Dis. 2016 Jul 1;214(1):55-64. doi: 10.1093/infdis/jiw077. Epub 2016 Feb 24.

8.

Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.

Dumond JB, Francis O, Cottrell M, Trezza C, Prince HM, Mollan K, Sykes C, Torrice C, White N, Malone S, Wang R, Van Dam C, Patterson KB, Hudgens MG, Sharpless NE, Forrest A.

Antivir Ther. 2016;21(5):441-5. doi: 10.3851/IMP3017. Epub 2016 Jan 5.

9.

No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.

Salem AH, Jones AK, Santini-Oliveira M, Taylor GP, Patterson KB, Nilius AM, Klein CE.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):400-8. doi: 10.1128/AAC.01197-15. Print 2016 Jan.

10.

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).

Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince HA, Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, Elharrar V, Mayer KH, Patterson KB.

AIDS Res Hum Retroviruses. 2016 Jan;32(1):32-43. doi: 10.1089/AID.2015.0182. Epub 2015 Oct 15.

11.

Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.

Floris-Moore MA, Mollan K, Wilkin AM, Johnson MA, Kashuba AD, Wohl DA, Patterson KB, Francis O, Kronk C, Eron JJ.

Antivir Ther. 2016;21(1):55-64. doi: 10.3851/IMP2982. Epub 2015 Aug 11.

12.

Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.

Cottrell ML, Patterson KB, Prince HM, Jones A, White N, Wang R, Kashuba AD.

Antivir Ther. 2015;20(8):795-803. doi: 10.3851/IMP2968. Epub 2015 Jun 3.

13.

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team.

Clin Infect Dis. 2015 Jun 15;60(12):1842-51. doi: 10.1093/cid/civ193. Epub 2015 Mar 12.

14.

Models for predicting effective HIV chemoprevention in women.

Nicol MR, Emerson CW, Prince HM, Nelson JA, Fedoriw Y, Sykes C, Geller EJ, Patterson KB, Cohen MS, Kashuba AD.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):369-76. doi: 10.1097/QAI.0000000000000472.

15.

Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women.

Rahangdale L, De Paris K, Kashuba AD, Nelson JA, Cottrell M, Sykes C, Emerson C, Young SL, Stevens T, Patterson KB, Cohen MS.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):420-4. doi: 10.1097/QAI.0000000000000480.

16.

Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):I-22. doi: 10.7326/P14-9035. No abstract available.

PMID:
25285557
17.

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Erratum in: Ann Intern Med. 2014 Nov 4;161(9):680.

18.

"I should know better": the roles of relationships, spirituality, disclosure, stigma, and shame for older women living with HIV seeking support in the South.

Grodensky CA, Golin CE, Jones C, Mamo M, Dennis AC, Abernethy MG, Patterson KB.

J Assoc Nurses AIDS Care. 2015 Jan-Feb;26(1):12-23. doi: 10.1016/j.jana.2014.01.005. Epub 2014 Mar 12.

19.

Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention.

Nicol MR, Fedoriw Y, Mathews M, Prince HM, Patterson KB, Geller E, Mollan K, Mathews S, Kroetz DL, Kashuba AD.

J Clin Pharmacol. 2014 May;54(5):574-83. doi: 10.1002/jcph.248. Epub 2014 Jan 2.

20.

Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.

Patterson KB, Prince HA, Stevens T, Shaheen NJ, Dellon ES, Madanick RD, Jennings S, Cohen MS, Kashuba AD.

AIDS. 2013 Jun 1;27(9):1413-9. doi: 10.1097/QAD.0b013e32835f2b49.

21.

Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.

Greener BN, Patterson KB, Prince HM, Sykes CS, Adams JL, Dumond JB, Shaheen NJ, Madanick RD, Dellon ES, Cohen MS, Kashuba AD.

J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):39-44. doi: 10.1097/QAI.0b013e31829ed7a4.

22.

Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.

Adams JL, Patterson KB, Prince HM, Sykes C, Greener BN, Dumond JB, Kashuba AD.

Antivir Ther. 2013;18(8):1005-13. doi: 10.3851/IMP2665. Epub 2013 Jul 31.

23.

Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment.

Zhang X, Hunt PW, Hammer SM, Cespedes MS, Patterson KB, Bosch RJ.

HIV Clin Trials. 2013 Mar-Apr;14(2):61-7. doi: 10.1310/hct1402-61.

24.

Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.

Dumond JB, Adams JL, Prince HM, Kendrick RL, Wang R, Jennings SH, Malone S, White N, Sykes C, Corbett AH, Patterson KB, Forrest A, Kashuba AD.

HIV Med. 2013 Aug;14(7):401-9. doi: 10.1111/hiv.12017. Epub 2013 Feb 24.

25.

Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.

Patterson KB, Dumond JB, Prince HA, Jenkins AJ, Scarsi KK, Wang R, Malone S, Hudgens MG, Kashuba AD.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):51-8. doi: 10.1097/QAI.0b013e31827fd47e.

26.

Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?

Adams JL, Sykes C, Menezes P, Prince HM, Patterson KB, Fransen K, Crucitti T, De Baetselier I, Van Damme L, Kashuba AD.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):260-6. doi: 10.1097/QAI.0b013e3182794723.

27.

Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.

Dumond JB, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, Cohen MS, Forrest A, Kashuba AD.

Clin Pharmacokinet. 2012 Dec;51(12):809-22. doi: 10.1007/s40262-012-0012-y.

28.

Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.

Brown KC, Patterson KB, Jennings SH, Malone SA, Shaheen NJ, Asher Prince HM, Spacek M, Cohen MS, Kashuba AD.

J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):138-44.

29.

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.

Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, Kashuba AD.

Sci Transl Med. 2011 Dec 7;3(112):112re4. doi: 10.1126/scitranslmed.3003174.

30.

Pre-exposure prophylaxis for HIV prevention: how to predict success.

Kashuba AD, Patterson KB, Dumond JB, Cohen MS.

Lancet. 2012 Jun 30;379(9835):2409-2411. doi: 10.1016/S0140-6736(11)61852-7. Epub 2011 Dec 6. No abstract available.

31.

Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.

Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HM, Dumond JB, Spacek MB, Heidt PE, Cohen MS, Kashuba AD.

J Infect Dis. 2011 May 15;203(10):1484-90. doi: 10.1093/infdis/jir059.

32.

A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.

Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD.

Clin Pharmacol Ther. 2010 Jun;87(6):735-42. doi: 10.1038/clpt.2009.253. Epub 2010 Feb 10.

33.

Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200.

Para MF, Schouten J, Rosenkranz SL, Yu S, Weiner D, Tebas P, White CJ, Reeds D, Lertora J, Patterson KB, Daar ES, Cavert W, Brizz B; ACTG A5200 Team of the ACTG.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):491-5. doi: 10.1097/QAI.0b013e3181d142cb.

34.

Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies.

Patterson KB, Cohn SE, Uyanik J, Hughes M, Smurzynski M, Eron JJ.

Clin Infect Dis. 2009 Aug 1;49(3):473-6. doi: 10.1086/600398.

35.

Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.

Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, Tressler R, Worsley J, Kashuba AD.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):546-53. doi: 10.1097/QAI.0b013e3181ae69c5.

36.

Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.

Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, Chen YC, Vourvahis M, Horton AL, Fiscus SA, Patterson KB.

Antimicrob Agents Chemother. 2009 Jun;53(6):2367-74. doi: 10.1128/AAC.01523-08. Epub 2009 Mar 23.

37.

Evaluation of the repertoire of the TonB-dependent receptors of Haemophilus ducreyi for their role in virulence in humans.

Leduc I, Banks KE, Fortney KR, Patterson KB, Billings SD, Katz BP, Spinola SM, Elkins C.

J Infect Dis. 2008 Apr 15;197(8):1103-9. doi: 10.1086/586901.

PMID:
18462159
38.

The pharmacokinetics and viral activity of tenofovir in the male genital tract.

Vourvahis M, Tappouni HL, Patterson KB, Chen YC, Rezk NL, Fiscus SA, Kearney BP, Rooney JF, Hui J, Cohen MS, Kashuba AD.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):329-33. doi: 10.1097/QAI.0b013e3181632cc3.

39.

Frequent detection of acute HIV infection in pregnant women.

Patterson KB, Leone PA, Fiscus SA, Kuruc J, McCoy SI, Wolf L, Foust E, Williams D, Eron JJ, Pilcher CD.

AIDS. 2007 Nov 12;21(17):2303-8.

PMID:
18090278
40.

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, Bridges AS, Stewart PW, Cohen MS, Kashuba AD.

AIDS. 2007 Sep 12;21(14):1899-907.

41.

Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV.

Witt KL, Cunningham CK, Patterson KB, Kissling GE, Dertinger SD, Livingston E, Bishop JB.

Environ Mol Mutagen. 2007 Apr-May;48(3-4):322-9.

42.

Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.

Corbett AH, Patterson KB, Tien HC, Kalvass LA, Eron JJ, Ngo LT, Lim ML, Kashuba AD.

Antimicrob Agents Chemother. 2006 Aug;50(8):2756-61.

43.

Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.

Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD.

J Acquir Immune Defic Syndr. 2006 May;42(1):52-60.

PMID:
16639344
44.
45.

Smallpox and the Native American.

Patterson KB, Runge T.

Am J Med Sci. 2002 Apr;323(4):216-22. Review.

PMID:
12003378
46.

The history of heart transplantation.

Patterson C, Patterson KB.

Am J Med Sci. 1997 Sep;314(3):190-7. No abstract available.

PMID:
9298045
47.

Paget's disease of the male breast.

Johnson TJ, Tomek CS, Patterson KB, Buckley JF.

Nebr Med J. 1987 Jan;72(1):10-3. No abstract available.

PMID:
3029611

Supplemental Content

Loading ...
Support Center